Brief: Pharnext H1 Operating Loss Widens To EUR 13.2 Mln

Neovacs SA

17/10/2022 07:32

Oct 17 (Reuters) - PHARNEXT SA  PHARN.PA :
    * PHARNEXT REPORTS FIRST HALF 2022 FINANCIAL RESULTS
    * ON-SCHEDULE COMPLETION OF PATIENT ENROLLMENT IN PIVOTAL
PHASE
III CLINICAL STUDY OF PXT3003, PREMIER TRIAL, IN
CHARCOT-MARIE-TOOTH DISEASE TYPE 1A ('CMT1A') WITH TOP-LINE
RESULTS EXPECTED IN Q4 2023
    * NEW DATA FROM ONGOING OPEN-LABEL PHASE III EXTENSION STUDY
OF
PXT3003, PLEO-CMT-FU TRIAL, SHOWS SUSTAINED TREATMENT BENEFIT IN
PATIENTS WITH CMT1A
    * POST-PERIOD EUR 20.7 MILLION FINANCING AGREEMENT WITH
NÉOVACS TO
FURTHER ADVANCE DEVELOPMENT OF PXT3003 IN CMT1A
    * NET LOSS IN H1 2022 WAS EUR 19.1 MILLION, COMPARED TO A
LOSS OF
EUR 13.6 MILLION IN H1 2021
    * CASH POSITION AT JUNE 30, 2022 WAS EUR 1.2 MILLION, A
DECREASE
OF EUR 6.8 MILLION IN PERIOD
    * H1 OPERATING LOSS EUR 13.2 MILLION VERSUS EUR 11.2 MILLION
YEAR
AGO

Source text for Eikon:  ID:nEQ1dWkxVa 
Further company coverage:  PHARN.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))